ZIM Laboratories Limited (NSE:ZIMLAB)
116.52
-2.06 (-1.74%)
Jul 22, 2026, 3:15 PM IST
ZIM Laboratories Revenue
In the fiscal year ending March 31, 2026, ZIM Laboratories had annual revenue of 3.74B INR, down -1.22%. ZIM Laboratories had revenue of 1.05B in the quarter ending March 31, 2026, a decrease of -3.18%.
Revenue
3.74B
Revenue Growth
-1.22%
P/S Ratio
1.75
Revenue / Employee
5.92M
Employees
632
Market Cap
6.56B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.74B | -46.31M | -1.22% |
| Mar 31, 2025 | 3.79B | 115.14M | 3.13% |
| Mar 31, 2024 | 3.68B | -310.92M | -7.80% |
| Mar 31, 2023 | 3.99B | 651.00M | 19.52% |
| Mar 31, 2022 | 3.34B | 261.64M | 8.51% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Windlas Biotech | 9.04B |
| Ind-Swift Laboratories | 6.41B |
| Sigachi Industries | 4.86B |
| Beta Drugs | 3.85B |
| Jagsonpal Pharmaceuticals | 2.87B |
| Sakar Healthcare | 2.52B |
| Valiant Laboratories | 2.37B |
ZIM Laboratories News
- 8 months ago - Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules - Business Upturn
- 1 year ago - ZIM Laboratories secures marketing authorization in Australia for urology drug combination - Business Upturn
- 1 year ago - ZIM Laboratories shares in focus as company gets first marketing approval in Australia - Business Upturn